Free Trial
OTCMKTS:INBP

Integrated BioPharma (INBP) Stock Price, News & Analysis

Integrated BioPharma logo
$0.29 +0.00 (+0.69%)
As of 11:51 AM Eastern

About Integrated BioPharma Stock (OTCMKTS:INBP)

Key Stats

Today's Range
$0.29
$0.29
50-Day Range
$0.26
$0.35
52-Week Range
$0.16
$0.42
Volume
2,500 shs
Average Volume
21,409 shs
Market Capitalization
$8.85 million
P/E Ratio
9.74
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Receive INBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter.

INBP Stock News Headlines

Integrated Biopharma Inc (INBP)
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Integrated BioPharma, Inc. (INBP)
See More Headlines

INBP Stock Analysis - Frequently Asked Questions

Integrated BioPharma's stock was trading at $0.3297 at the beginning of the year. Since then, INBP stock has decreased by 11.4% and is now trading at $0.2920.
View the best growth stocks for 2025 here
.

Integrated BioPharma, Inc. (OTCMKTS:INBP) posted its earnings results on Wednesday, May, 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm earned $13.95 million during the quarter. Integrated BioPharma had a trailing twelve-month return on equity of 4.79% and a net margin of 1.78%.

Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP).

Company Calendar

Last Earnings
5/14/2025
Today
5/30/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:INBP
Employees
150
Year Founded
N/A

Profitability

Trailing P/E Ratio
9.67
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$110 thousand
Pretax Margin
2.79%

Debt

Sales & Book Value

Annual Sales
$50.32 million
Cash Flow
$0.04 per share
Price / Cash Flow
7.35
Book Value
$0.65 per share
Price / Book
0.45

Miscellaneous

Free Float
9,939,000
Market Cap
$8.79 million
Optionable
Not Optionable
Beta
0.80

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (OTCMKTS:INBP) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners